A Randomized Phase III Study to Compare Efficacy and Safety of BAT2206 (Proposed Ustekinumab Biosimilar) with Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis.

BAT2206 (ustekinumab biosimilar) - Bio-Thera Solutions, Pharmapark, Hikma, Biomm, Gedeon Richter

http://www.ncbi.nlm.nih.gov/pubmed/39592058

Agnieszka Zebrowska; Cailing Gu; Katya Zaharieva; Lally Mekokishvili; Min Zheng; Qingfeng Dong; Xiaolei Yang; Xiaoyong Man; Yunhua Deng; Yunpeng Qi

Nov 27, 2024